Von Willebrand DiseasesWILLANGIONCT04810702
Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
An observational study of Von Willebrand Diseases, run by Nantes University Hospital at 1 site in France.
Trial summary
The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Von Willebrand Diseases
- How many people
- 109 participants
- Where
- 1 siteFrance
- Study dates
- 7 Feb 2024to 1 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The studied population will be composed of: * 70 patients with von Willebrand disease: 10 type 1 patients, 10 type 2A (IIA) patients, 10 type 2A (IIE) patients, 10 type 2B patients, 10 type 2M patients, 10 type 2M patients (2A-like) and 10 type 3 patients. * 20 healthy volunteers
Who may be able to join
- For patients:
- Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
- Lack of treatment that could interfere with angiogenesis.
- Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
- For the control:
- Patient with a normal coagulation report
Show all 10Show fewer
- Absence of abnormal hemorrhagic symptoms
- Lack of notion of angiodysplasia.
- Lack of treatment that could interfere with angiogenesis.
- Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
Who cannot join
- Patient under guardianship or curatorship.
- Pregnant and lactating women.
- Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
- Treatment which may interfere with angiogenesis.
Trial locations and contacts
1 site in 1 country.
About this study
The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.
- Conditions
- Von Willebrand Diseases
- Being tested
- no intervention
- Medical subject headings
- von Willebrand Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no interventionOther
no intervention
| Study group | Role | What they receive |
|---|---|---|
| patients with von Willebrand disease | Not described Receives: Other: no intervention | |
| case control | Not described Receives: Other: no intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest
Compare the distribution of multimers assays between different groups of patients and the control group
Measured: 1 year
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest
Compare the distribution of protein assays between different groups of patients and the control group
Measured: 1 year
Secondary outcomes (2)
To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias
To study the correlation between the clinical phenotype and the assays of angiogenesis proteins
Measured: 1 year
To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias
To study the correlation between the clinical phenotype and the distribution of multimers
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2021
- Study start7 Feb 2024
- Primary completion1 Nov 2025
- Study completion1 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Von Willebrand DiseasesStudies of the same condition, open and under way.
- More trials run by Nantes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 109 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nantes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04810702
- Sponsor's protocol ID
- RC20_0531
- Acronym
- WILLANGIO
- Status last verified
- Sep 2026
- First submitted
- 16 Mar 2021
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Von Willebrand Factor and Its Multimers on Angiogenesis
- ClinicalTrials.gov ID
- NCT04810702
- Acronym / sponsor ID
- WILLANGIO / RC20_0531
- Conditions
- Von Willebrand Diseases
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 109 participants (actual)
- Lead sponsor
- Nantes University HospitalUniversity, hospital or other
- Study start
- 7 Feb 2024 (actual)
- Primary completion
- 1 Nov 2025 (actual)
- Study completion
- 1 Nov 2025 (actual)
- First posted
- 23 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients with von Willebrand disease | – | Other: no intervention |
| case control | – | Other: no intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The studied population will be composed of: * 70 patients with von Willebrand disease: 10 type 1 patients, 10 type 2A (IIA) patients, 10 type 2A (IIE) patients, 10 type 2B patients, 10 type 2M patients, 10 type 2M patients (2A-like) and 10 type 3 patients. * 20 healthy volunteers
Key inclusion criteria (10 listed)
- Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
- Lack of treatment that could interfere with angiogenesis.
- Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.
- Patient with a normal coagulation report
- Absence of abnormal hemorrhagic symptoms
Key exclusion criteria (4 listed)
- Patient under guardianship or curatorship.
- Pregnant and lactating women.
- Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
- Treatment which may interfere with angiogenesis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no interventionno intervention | Other | case control, patients with von Willebrand disease |
Primary outcome
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest
Time frame: 1 year
Compare the distribution of multimers assays between different groups of patients and the control group
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest
Time frame: 1 year
Compare the distribution of protein assays between different groups of patients and the control group
2 secondary outcomes
To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias
Time frame: 1 year
To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Von Willebrand Diseases
Active, not recruitingObservational study
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Von Willebrand Disease, Type 3
RecruitingObservational study
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Heavy Menstrual Bleeding, Bleeding Disorder
RecruitingPhase 2
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
RecruitingObservational study
Blood Clotting Markers and Heart Ultrasound in People With Device-Detected Atrial Fibrillation
Device-detected Atrial Fibrillation, Subclinical Atrial Fibrillation
RecruitingPhase 3
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD
Von Willebrand Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Von Willebrand Diseases, run by Nantes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest (time frame: 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.